or Try an Advanced Search...

    Technical Analysis for MLTX - MoonLake Immunotherapeutics

    Grade Last Price % Change Price Change
    D 45.26 6.32% 2.69
    MLTX closed up 6.32 percent on Friday, May 3, 2024, on 77 percent of normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical MLTX trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Gapped Up Strength 0.00%
    20 DMA Resistance Bearish 6.32%
    Slingshot Bearish Bearish Swing Setup 5.65%
    MACD Bullish Signal Line Cross Bullish 5.65%
    MACD Bearish Signal Line Cross Bearish 10.63%
    Spinning Top Other 10.63%
    Stochastic Reached Oversold Weakness 10.63%
    Gapped Down Weakness 10.63%
    Oversold Stochastic Weakness 10.63%
    Older End-of-Day Signals for MLTX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 5 hours ago
    20 DMA Support about 6 hours ago
    Up 5% about 8 hours ago
    Up 3% about 9 hours ago
    Up 1 ATR about 9 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    MLTX Chart by TradingView
    Basic chart:

    Profile

    MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, the first investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients. Sonelokimab optimally inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. The Company’s focus is on inflammatory diseases with a major unmet need with lead indications currently progressing into Phase 2 trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis or radiographic axial spondyloarthritis. MoonLake is headquartered in Zug, Switzerland.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Clinical Medicine Organ Systems Autoimmune Disease Inflammation Inflammatory Diseases Arthritis Rheumatology Psoriatic Arthritis Hidradenitis Suppurativa Interleukin 17 Interleukins Spondylitis

    Is MLTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 10 MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
    Apr 2 Goldman starts MoonLake at neutral, cites lead drug potential
    Mar 11 MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
    Mar 10 MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
    Mar 4 MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
    Mar 1 Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)
    Feb 29 MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
    Feb 26 MoonLake gets FDA, EMA feedback on Phase 3 study
    Feb 26 MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
    Feb 26 MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
    See more MLTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 64.98
    52 Week Low 24.31
    Average Volume 488,043
    200-Day Moving Average 52.54
    50-Day Moving Average 46.72
    20-Day Moving Average 43.43
    10-Day Moving Average 42.48
    Average True Range 2.00
    RSI (14) 52.61
    ADX 19.37
    +DI 22.69
    -DI 21.66
    Chandelier Exit (Long, 3 ATRs) 41.72
    Chandelier Exit (Short, 3 ATRs) 46.45
    Upper Bollinger Bands 46.82
    Lower Bollinger Band 40.04
    Percent B (%b) 0.77
    BandWidth 15.61
    MACD Line -1.32
    MACD Signal Line -1.72
    MACD Histogram 0.4012
    Fundamentals Value
    Market Cap 2.71 Billion
    Num Shares 59.9 Million
    EPS -1.06
    Price-to-Earnings (P/E) Ratio -42.70
    Price-to-Sales 0.00
    Price-to-Book 8.64
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 48.35
    Resistance 3 (R3) 48.08 46.77 47.84
    Resistance 2 (R2) 46.77 45.98 46.91 47.66
    Resistance 1 (R1) 46.02 45.50 46.39 46.29 47.49
    Pivot Point 44.71 44.71 44.90 44.85 44.71
    Support 1 (S1) 43.96 43.92 44.33 44.23 43.03
    Support 2 (S2) 42.65 43.44 42.79 42.86
    Support 3 (S3) 41.90 42.65 42.69
    Support 4 (S4) 42.17